Chronic Kidney Disease in Cats: Welfare-Oriented Management

Chronic Kidney Disease in Cats: A Major Geriatric Welfare Challenge

Chronic kidney disease (CKD) is the most common disease of older cats, affecting approximately 30-40% of cats over 10 years and 80% of cats over 15 years. It is the leading cause of death in older cats. As feline longevity increases with improved veterinary care and nutrition, managing CKD welfare effectively becomes an increasingly important veterinary priority.

Pathophysiology

CKD involves progressive, irreversible loss of nephrons (functional kidney units). The remaining nephrons hypertrophy and hyperfiltrate to compensate, but this compensation is ultimately insufficient. As renal mass declines, multiple metabolic derangements develop: uraemia (accumulation of protein metabolic waste products), metabolic acidosis, hypokalaemia, hypertension, and secondary renal anaemia.

IRIS Staging System

The International Renal Interest Society (IRIS) staging system (I-IV based on serum creatinine and SDMA) guides management and enables communication between veterinarians. Stage I-II (early): often subclinical or mildly symptomatic. Stage III: progressive azotaemia, clinical signs. Stage IV: severe uraemia, life-threatening.

Clinical Signs and Welfare Impacts

• Polyuria/polydipsia: Increased water intake and urination from loss of urinary concentrating ability
• Weight loss: Muscle wasting from uraemia-induced protein catabolism and reduced appetite
• Reduced appetite and nausea: Uraemic toxins cause gastric irritation and nausea — significant welfare concern
• Lethargy and weakness: Anaemia and uraemia reduce energy and activity
• Hypertension: Systemic hypertension causing blindness (hypertensive retinopathy), cardiac changes, and neurological signs
• Hypokalaemia: Muscle weakness and ventroflexion of neck in severe cases

Welfare-Oriented Management

Hydration: Adequate water intake is critical — encouraging water through multiple sources, water fountains, and wet food. Subcutaneous fluid therapy (SQ fluids given at home by trained owners) dramatically improves quality of life in stages III-IV, flushing uraemic toxins and maintaining hydration.

Dietary management: Renal diets with restricted phosphorus, reduced protein, and supplemented omega-3 fatty acids slow progression (IRIS guidelines recommend dietary phosphorus restriction from Stage II). Palatability is paramount — inadequate intake from unpalatable renal diets worsens outcomes.

Anti-nausea medications: Maropitant, ondansetron, or omeprazole reduce nausea and improve appetite and welfare significantly.

Hypertension treatment: Amlodipine is first-line treatment for hypertension, preventing devastating end-organ damage.

Anaemia management: Darbepoetin (erythropoiesis-stimulating agent) corrects renal anaemia in eligible patients, dramatically improving activity and quality of life.

Quality of Life Monitoring

Regular quality of life assessment guides management decisions. Owners track appetite, activity, grooming, interaction, and comfort weekly. When good days become fewer than bad days despite optimal management, honest end-of-life discussions support welfare-centred decision-making.

This page is part of the Animal Welfare Hub — providing evidence-based information to improve the lives of animals. Return to home.